Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021; 23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Felix Gonzalez-Torres' and Gregg Bordowitz’s works express their experiences of living through a pandemic and subsequent social change and draw out key human rights themes.
AMA J Ethics. 2020; 22(9):E821-829. doi:
10.1001/amajethics.2020.821.
Prevention efforts can marginalize patients by stigmatizing certain behaviors, so distinguishing individual professionals’ preferences about those behaviors is critical.
AMA J Ethics. 2019; 21(6):E536-539. doi:
10.1001/amajethics.2019.536.
Dichotomies, such as reconstructive vs aesthetic surgery and medical vs cosmetic dermatology, can distort meanings of surgical procedures. This can compromise the value of procedures themselves and practices for their reimbursement.
AMA J Ethics. 2018; 20(12):E1188-1194. doi:
10.1001/amajethics.2018.1188.
Lee C. Zhao, MD, Gaines Blasdel, Augustus Parker, and Rachel Bluebond-Langner, MD
Tension between realistic goals and unrealistic views about how to achieve them is compounded when patients are eager to revise a prior surgeon’s gender-affirming procedure.
AMA J Ethics. 2023; 25(6):E391-397. doi:
10.1001/amajethics.2023.391.
When confidential medical information can prevent a serious harm to a third party, the patient’s prima facie right to confidentiality must be balanced against the physician’s prima facie obligation to prevent serious harm to that third party.
AMA J Ethics. 2015; 17(9):819-825. doi:
10.1001/journalofethics.2015.17.9.ecas1-1509.